{"ModuleTitle": "Company Description", "CompanyName": "Adamas Pharmaceuticals, Inc.", "Symbol": "ADMS", "Address": "1900 POWELL ST., SUITE 1000, EMERYVILLE, California, 94608, United States of America", "Phone": "510-450-3554", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "At Adamas Pharmaceuticals, Inc., our purpose is to make everyday life\r\nsignificantly better for people affected by neurological diseases. We are\r\nturning this purpose into reality by combining our proven expertise in\r\ndiscovery, development and commercialization with our passion for improving\r\nlives. We believe our medicines should be clinically differentiated and provide\r\na meaningful benefit to patients. With one partnered product and a commercial\r\nmedicine, we are focused on growing a portfolio of therapies to reduce the\r\nburden of neurological diseases on patients, caregivers, and society.\r\nOur portfolio includes:\r\nApproved Product:\r\n*GOCOVRI\u00ae (amantadine) extended release capsules, is the first and only\r\nFDA-approved medication indicated for the treatment of dyskinesia in patients\r\nwith Parkinson's disease receiving levodopa-based therapy, with or without\r\nconcomitant dopaminergic medications.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001328143-20-000012.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Christopher B. Prentiss", "title": "Chief Financial Officer"}, {"name": "Neil F. McFarlane", "title": "Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}